Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose
- PMID: 2948443
- PMCID: PMC176523
- DOI: 10.1128/AAC.30.5.733
Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose
Abstract
The pharmacokinetic profile of [14C]teicoplanin was studied in male Sprague-Dawley rats given a single 10,000-U/kg intravenous dose. The disposition of the antimicrobial activity in the body was estimated by a three-compartment open model. Plasma concentration data were fitted to a three-exponent equation. The profile of total 14C in plasma was similar to that of the microbiological activity. The cumulative recovery of total 14C 5 days after drug administration averaged 76.3% of the administered dose in the urine and 8.7% in the feces. The residual dose remaining in the animal carcasses was 11.1%. Teicoplanin was widely distributed in the body. In almost all organs, the maximum concentration of [14C]teicoplanin was already reached at the first time of killing, which was 0.25 h after the administration of drug. The liver, kidneys, skin, and fat contained most of the residual dose found in the animal carcasses 120 h after administration and behaved as a deep compartment with the adrenal glands and spleen.
Similar articles
-
Clinical pharmacokinetics of teicoplanin.Clin Pharmacokinet. 1990 Mar;18(3):184-209. doi: 10.2165/00003088-199018030-00002. Clin Pharmacokinet. 1990. PMID: 2138946 Review.
-
Distribution and excretion of teicoplanin in rats after single and repeated intravenous administration.Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:85-93. Eur J Drug Metab Pharmacokinet. 1991. PMID: 1840327
-
Teicoplanin pharmacokinetics in patients with chronic renal failure.Clin Pharmacokinet. 1987 Apr;12(4):292-301. doi: 10.2165/00003088-198712040-00003. Clin Pharmacokinet. 1987. PMID: 2954735
-
Pharmacokinetics of teicoplanin in the elderly.J Antimicrob Chemother. 1988 Jan;21 Suppl A:39-45. doi: 10.1093/jac/21.suppl_a.39. J Antimicrob Chemother. 1988. PMID: 2965130
-
Comparative pharmacokinetics of teicoplanin and vancomycin.J Chemother. 2000 Nov;12 Suppl 5:15-20. doi: 10.1080/1120009x.2000.11782313. J Chemother. 2000. PMID: 11131959 Review.
Cited by
-
Teicoplanin metabolism in rats.Antimicrob Agents Chemother. 1989 Oct;33(10):1791-4. doi: 10.1128/AAC.33.10.1791. Antimicrob Agents Chemother. 1989. PMID: 2531569 Free PMC article.
-
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585. Antimicrob Agents Chemother. 1995. PMID: 8585753 Free PMC article.
-
Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat.Antimicrob Agents Chemother. 1995 Oct;39(10):2176-82. doi: 10.1128/AAC.39.10.2176. Antimicrob Agents Chemother. 1995. PMID: 8619562 Free PMC article.
-
Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies.Adv Ther. 2024 Jul;41(7):2966-2977. doi: 10.1007/s12325-024-02884-z. Epub 2024 May 14. Adv Ther. 2024. PMID: 38743241
-
Clinical pharmacokinetics of teicoplanin.Clin Pharmacokinet. 1990 Mar;18(3):184-209. doi: 10.2165/00003088-199018030-00002. Clin Pharmacokinet. 1990. PMID: 2138946 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical